Regional Citrate Anticoagulation During Continuous Renal Replacement Therapy; Should It Be the First Choice Over Heparin in Children?
Therapeutic Apheresis and Dialysis · 2025
DOI: 10.1111/1744-9987.70087 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Apheresis and Dialysis, 2025. Verfasst von Guntulu Sık. Beteiligte Einrichtung: Department of Pediatric Intensive Care, School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. Hauptthemen laut MEDLINE: Heparin, Anticoagulants, Continuous Renal Replacement Therapy, Citric Acid. Die Arbeit nennt 33 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Regional citrate anticoagulation (RCA) has gained increasing attention as a superior anticoagulation strategy in pediatric continuous renal replacement therapy (CRRT). Compared to systemic heparin anticoagulation (SHA), RCA offers significant advantages, including prolonged circuit lifespan, reduced clotting rates, and a lower incidence of bleeding complications. While heparin remains widely used due to its availability and ease of administration, its systemic effects, particularly the risk of bleeding and heparin‐induced thrombocytopenia, pose considerable challenges in critically ill children. Studies have consistently demonstrated that RCA reduces transfusion requirements and enhances circuit survival without increasing bleeding risk. Despite potential metabolic concerns such as citrate accumulation, metabolic alkalosis, and electrolyte imbalances, these risks can be effectively managed with careful monitoring and protocol adjustments. As pediatric CRRT protocols continue to evolve, RCA is emerging as the preferred first‐line anticoagulation method, particularly in patients with high bleeding risk. The growing body of evidence supports its wider clinical application, promising better treatment outcomes and improved survival rates in critically ill pediatric patients requiring CRRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Intensive Care, School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
ORCID-Profile: Guntulu Sık
Zitieren
APA
Sık, G. (2025). Regional Citrate Anticoagulation During Continuous Renal Replacement Therapy; Should It Be the First Choice Over Heparin in Children?. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.70087
Vancouver
Sık G. Regional Citrate Anticoagulation During Continuous Renal Replacement Therapy; Should It Be the First Choice Over Heparin in Children?. Therapeutic Apheresis and Dialysis. 2025. doi:10.1111/1744-9987.70087
BibTeX
@article{Sk2025,
author = {Sık, Guntulu},
title = {Regional Citrate Anticoagulation During Continuous Renal Replacement Therapy; Should It Be the First Choice Over Heparin in Children?},
journal = {Therapeutic Apheresis and Dialysis},
year = {2025},
doi = {10.1111/1744-9987.70087}
}
EUVIMED